Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) are celebrating approval of their blood-thinning drug Eliquis in Europe for atrial fibrillation. In this video, Motley Fool health care analyst David Williamson talks about why the approval was largely expected and therefore didn't drive share prices much, why the drug's U.S. rejection back in June was more of a minor setback than a major blow, and just how big of a drug this is going to be for both companies.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Pfizer and Bristol-Myers' Major New Drug Approval
NYSE: PFE
Pfizer

This new drug just approved in Europe is due to be the industry standard.
Brenton Flynn has no positions in the stocks mentioned above. David Williamson owns shares of Johnson & Johnson and Pfizer. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.